#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2018 - 6

Current trends in the diagnosis and treatment of gastroesophageal reflux disease

Czech version

Authors: Radek Kroupa;  Štefan Konečný;  Jiří Dolina
Authors‘ workplace: Interní gastroenterologická klinika LF MU a FN Brno, pracoviště Bohunice
Published in: Vnitř Lék 2018; 64(6): 588-594
Category: Reviews

Overview

Gastroesophageal reflux disease and its typical symptoms heartburn and regurgitation is one of the most common gastrointestinal disorders. Besides esophageal symptoms awareness of extraesophageal symptoms is increasing. The diagnosis is usually based on history of symptoms and on endoscopically visible esophageal injury in some patients. Normal endoscopic finding and refractory symptoms on standard treatment should evoke further examination. Proton pump inhibitors have been the mainstay of medical therapy. Long term maintenance treatment may raise awareness of side effects and therapeutic alternatives. This review is focused of current available diagnostic and therapeutic strategies for gastroesophageal reflux disease.

Key words:

Barrett´s esophagus – esophageal impedance – esophageal stricture – fundoplication – gastroeso­phageal reflux – gastroesophageal reflux disease – proton pump inhibitors

Sources
  1. Vakil N, Zanten SV van, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101(8): 1900–1920; quiz 1943. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572–0241.2006.00630.x>.
  2. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108(3): 308–328; quiz 329. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2012.444>. Erratum in Am J Gastroenterol 2013; 108(10):1672.
  3. Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis – a spectrum of disease or special entities? Z Gastroenterol 2007; 45(11): 1156–1163. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2007–963628>.
  4. Poh CH, Navarro-Rodriguez T, Fass R. Review: treatment of gastroesophageal reflux disease in the elderly. Am J Med 2010; 123(6): 496–501. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2009.07.036>.
  5. El-Serag HB, Sweet S, Winchester CC et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63(6): 871–880. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–304269>.
  6. Lukáš K, Bureš J, Drahoňovský V et al. Refluxní choroba jícnu. Standardy České gastroenterologické společnosti – aktualizace 2009. Vnitř Lék 2009; 55(10): 967–975.
  7. Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet 2013; 381(9881): 1933–1942. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)62171–0>.
  8. Seifert B. Dítě P, Bureš J et al. Gastroenterologie: doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Novelizace 2012. Společnost všeobecného lékařství ČLS JEP: 2012. ISBN: 978–80–86998–55–8. Dostupné z WWW: <http://www.medvik.cz/link/MED00178729.>.
  9. Shaheen NJ, Weinberg DS, Denberg TD et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2012; 157(11): 808–816. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–157–11–201212040–00008>.
  10. di Pietro M, Chan D, Fitzgerald RC et al. Screening for Barrett’s Esophagus. Gastroenterology 2015; 148(5): 912–923. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2015.02.012>.
  11. Benaglia T, Sharples LD, Fitzgerald RC et al. Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett’s Esophagus. Gastroenterology 2013; 144(1): 62–73. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2012.09.060>.
  12. Vaezi MF. Does my patient still have reflux when PPI therapy does not work? Neurogastroenterol Motil 2017; 29(5): e13065. Dostupné z DOI: <http://dx.doi.org/10.1111/nmo.13065>.
  13. Dolina J, Kala Z, Prokešová J et al. Nové možnosti v diagnostice refluxní nemoci jícnu. Čes Slov Gastroenterol Hepatol 2009; 63(4): 186–190.
  14. Heribanová L. Extraezofageální a gastroezofageální reflux – vztah k astma bronchiale. Gastroenterol Hepatol 2016; 70(5): 438–442.
  15. Kroupa R, Dolina J, Suchánková J et al. pHmetrie a manometrie. Současné postavení diagnostických metod. Čes Slov Gastroenterol Hepatol 2006; 60(4): 149–156.
  16. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6–30. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2016–312288>.
  17. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166(9): 965–971. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.166.9.965>.
  18. Ness-Jensen E, Hveem K, El-Serag H et al. Lifestyle Intervention in Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14(2): 175–182. e1-e3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2015.04.176>.
  19. Fujiwara Y, Arakawa T, Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol 2012; 47(7): 760–769. Dostupné z DOI: <http://dx.doi.org/10.1007/s00535–012–0601–4>.
  20. EBSCO DynaMed Plus website. Gastroesophageal reflux disease (GERD). Updated 2017. Dostupné z DOI: <http://www.dynamed.com/topics/dmp~AN~T116914/Gastroesophageal-reflux-disease-GERD>.
  21. Fass R, Sontag SJ, Traxler B et al. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4(1): 50–56.
  22. Boeckxstaens G, El-Serag HB, Smout AJPM et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014; 63(7): 1185–1193. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2013–306393>.
  23. Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver 2018; 12(1): 7–16. Dostupné z DOI: <http://dx.doi.org/10.5009/gnl16615>.
  24. Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus 2013; 26(1): 27–36. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1442–2050.2011.01322.x>.
  25. Surdea-Blaga T, Băncilă I, Dobru D et al. Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology. J Gastrointestin Liver Dis 2016; 25(4): 537–546. Dostupné z DOI: <http://dx.doi.org/10.15403/jgld.2014.1121.254.dea>.
  26. Kwiatek MA, Roman S, Fareeduddin A et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial “acid pocket” in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34(1): 59–66. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2011.04678.x>.
  27. Savarino V, Pace F, Scarpignato C et al. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther 2017; 45(5): 631–642. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13914>.
  28. Glicksman JT, Mick PT, Fung K et al. Prokinetic agents and laryngopharyngeal reflux disease: Prokinetic agents and laryngopharyngeal reflux disease: a systematic review. Laryngoscope 2014; 124(10): 2375–2379. Dostupné z DOI: <http://dx.doi.org/10.1002/lary.24738>.
  29. Zerbib F, Simon M. Novel therapeutics for gastro-esophageal reflux symptoms. Expert Rev Clin Pharmacol 2012; 5(5): 533–541. Dostupné z DOI: <http://dx.doi.org/10.1586/ecp.12.38>.
  30. Banerjee B, Shaheen NJ, Martinez JA et al. Clinical Study of Ursodeoxycholic Acid in Barrett’s Esophagus Patients. Cancer Prev Res Phila Pa 2016; 9(7): 528–533. Dostupné z DOI: <http://dx.doi.org/10.1158/1940–6207.CAPR-15–0276>.
  31. Kroupa R, Dolina J. Rizika dlouhodobé antisekreční léčby. Vnitř Lék 2010; 56(2): 115–119.
  32. Gomm W, Holt K von, Thomé F et al. Association of Proton Pump Inhibitors with Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 2016; 73(4): 410–416. Dostupné z DOI: <http://dx.doi.org/10.1001/jamaneurol.2015.4791>.
  33. Lazarus B, Chen Y, Wilson FP et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 2016; 176(2): 238–246. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2015.7193>.
  34. Sehested TS, Gerds TA, Fosbøl EL et al. Long-term use of Proton Pump Inhibitors, Dose-response Relationship, and Associated Risk of Ischemic Stroke and Myocardial Infarction. J Intern Med 2018; 283(3): 268–281. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.12698>.
  35. Ječmenová M, Kroupa R. Inhibitory protonové pumpy a kosti. Vnitř Lék 2016; 62(2): 139–146.
  36. Khan F, Maradey-Romero C, Ganocy S et al. Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Aliment Pharmacol Ther 2016; 43(11): 1124–1131. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.13611>.
  37. Hatlebakk JG, Zerbib F, Bruley des Varannes S et al. Gastroesophageal Acid Reflux Control 5 Years after Antireflux Surgery, Compared with Long-term Esomeprazole Therapy. Clin Gastroenterol Hepatol 2016; 14(5): 678–685. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2015.07.025>.
  38. Maret-Ouda J, Wahlin K, El-Serag HB et al. Association between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux. JAMA 2017; 318(10): 939–946. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2017.10981>.
  39. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2015; (11): CD003243. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD003243.pub3>.
  40. Warren HF, Reynolds JL, Lipham JC et al. Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease. Surg Endosc 2016; 30(8): 3289–3296. <http://dx.doi.org/10.1007/s00464–015–4659-y>.
  41. Konečný Š, Dolina J, Beneš Z et al. První případ elektrické stimulační terapie dolního jícnového svěrače indikovaný v České republice k implantaci. Gastroenterol Hepatol 2017; 71(2): 156–160.
  42. Casale M, Sabatino L, Moffa A et al. Breathing training on lower esophageal sphincter as a complementary treatment of gastroesophageal reflux disease (GERD): a systematic review. Eur Rev Med Pharmacol Sci 2016; 20(21): 4547–4552.
  43. Bitnar P, Stovicek J, Andel R et al. Leg raise increases pressure in lower and upper esophageal sphincter among patients with gastroesophageal reflux disease. J Bodyw Mov Ther 2016; 20(3): 518–524. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbmt.2015.12.002>.
  44. Shaheen NJ, Falk GW, Iyer PG et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2016; 111(1): 30–50; quiz 51. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2015.322>.
  45. Thrift AP, Kramer JR, Qureshi Z et al. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J Gastroenterol 2013; 108(6): 915–922. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2013.72>.
  46. Sikkema M, Jonge PJF de, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235–244; quiz e32. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2009.10.010>.
  47. de Jonge PJ, Blankenstein M van, Grady WM et al. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut 2014; 63(1): 191–202. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2013–305490>.
  48. Martínek J, Falt P, Gregar J et al. Standardy České gastroenterologické společnosti – endoskopická léčba pacientů s Barrettovým jícnem a časnými neoplaziemi jícnu. Gastroenterol Hepatol 2013; 67(6): 479–487.
  49. Maret-Ouda J, Konings P, Lagergren J et al. Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. Ann Surg 2016; 263(2): 251–257. Dostupné z DOI: <http://dx.doi.org/10.1097/SLA.0000000000001438>.
  50. Ham YH, Kim GH. Plastic and biodegradable stents for complex and refractory benign esophageal strictures. Clin Endosc 2014; 47(4): 295–300. Dostupné z DOI: <http://dx.doi.org/10.5946/ce.2014.47.4.295>.
  51. Pregun I, Hritz I, Tulassay Z et al. Peptic esophageal stricture: medical treatment. Dig Dis 2009; 27(1): 31–37. Dostupné z DOI: <http://dx.doi.org/10.1159/000210101>.
Labels
Diabetology Endocrinology Internal medicine
Therapy for peptic ulcer disease
History of celiac disease
Celiac disease in 2018
Diagnosis of gastrointestinal motility disorders
Diverticular disease: diagnosis and treatment
Familial adenomatous polyposis: complex patient management
Conventional and biological therapy for inflammatory bowel disease
The IBD outpatient care in the clinical practice
PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis
Possibilities of therapeutic manipulation of the gut microbiota
Prokinetics and their use in gastroenterology
Colorectal cancer screening
Therapeutic digestive endoscopy I
Therapeutic digestive endoscopy II
Article was published in

Internal Medicine

Issue 6
2018 Issue 6
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#